drugset / Trial / NCT03309657

Pharmacokinetics of Ceftolozane/Tazobactam in Plasma and Cerebrospinal Fluid

NCT03309657 ↗

NaSingle-groupOpen-labelBasic science

Summary

Ceftolozane/tazobactam is an emerging newly available antibiotic that has a broad spectrum of activity, and could be potentially useful in the management of central nervous system infections. However, data relating to penetration of ceftolozane/ tazobactam into the central nervous system, where a barrier against drug distribution exists (i.e. blood brain barrier), is currently limited. In critically ill patients this is all the more challenging as achieving adequate antibiotic concentrations even in blood is difficult. The aim of this study is to describe the concentrations achieved in the cerebrospinal fluid (i.e. bodily fluid found surrounding and inside of the brain) and blood after a single dose of ceftolozane/tazobactam administered in critically ill patients with an existing external ventricular drain (i.e. a device used in neurosurgery that relieves elevated intracranial pressure in the brain). It is planned that this information gained will help develop dosing strategies that will achieve target concentrations that will successfully treat central nervous system infections in the future.

Timeline

Start
2018-02-01
Primary completion
2020-05-01
Completion
2020-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ceftolozane/tazobactam Unknown 3000 mg —

Indications

No indication recorded.